Get informed when a big investor buys or sells
+ Follow27.87
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Astrazeneca plc (AZN) currently reports a P/E ratio of 27.87. That is below the Healthcare sector average of 70.94. Use the charts on this page to explore Astrazeneca plc's P/E ratio history and peer comparisons.
Astrazeneca plc's P/E ratio of 27.87 is lower than the Healthcare sector average of 70.94. That is roughly 60.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Astrazeneca plc's market price to a fundamental measure such as earnings, sales, or book value. At 27.87, AZN can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of 27.87, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 70.94. From there, open related valuation or income-statement pages for Astrazeneca plc, and consider following AZN for alerts when major investors trade the stock.
Astrazeneca plc is classified in the Healthcare sector. On P/E ratio, it currently shows 27.87 versus a sector average near 70.94. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AZN with unrelated industries.